Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium.
Bastian NeesgaardAmanda MocroftRobert ZangerleFerdinand WitFiona LampeHuldrych F GünthardCoca NecsoiMatthew LawCristina MussiniAntonella CastagnaAntonella d'Arminio MonforteChristian PradierNikoloz ChkhartisvilliJuliana Reyes-UruenaJörg Janne VehreschildJan-Christian WasmuthAnders SönnerborgChristoph StephanLauren GreenbergJosep M LlibreAlain Volny-AnneLars PetersAnnegret Pelchen-MatthewsVani VannappagariJoel GallantArmin RiegerMike YouleDominique BraunStephane De WitKathy PetoumenosVanni BorghiVincenzo SpagnuoloTengiz TsertsvadzeJens LundgrenLene Ryomnull nullPublished in: PloS one (2020)
In this large analysis of a real-world population, cTO and on-treatment success were similar between INSTIs and NNRTIs, but lower for PI/b, though residual confounding cannot be fully excluded. Obtaining favorable immunologic outcomes were more likely for INSTIs than the other drug classes.